Nifty
Sensex
:
:
11604.10
39058.83
15.75 (0.14%)
94.99 (0.24%)

Pharmaceuticals & Drugs

Rating :
46/99

BSE: 540222 | NSE: LAURUSLABS

348.00
23-Oct-2019
  • Open
  • High
  • Low
  • Previous Close
  •  344.45
  •  360.60
  •  341.70
  •  341.70
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  55919
  •  195.97
  •  412.05
  •  303.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,701.38
  • 39.89
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 4,734.29
  • 0.43%
  • 2.34

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 0%
  • 0%
  • 0%
  • FII
  • DII
  • Others
  • 0%
  • 0%
  • 0%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 11.56
  • 6.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 12.78
  • -2.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 6.60
  • -21.16

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 34.15

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 3.49

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 14.18

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
550.57
539.02
2.14%
635.16
560.24
13.37%
529.46
478.93
10.55%
588.28
538.61
9.22%
Expenses
467.31
458.46
1.93%
523.17
443.36
18.00%
441.74
391.58
12.81%
512.56
426.04
20.31%
EBITDA
83.26
80.55
3.36%
111.99
116.88
-4.18%
87.71
87.35
0.41%
75.73
112.57
-32.73%
EBIDTM
15.12%
14.94%
17.63%
20.86%
16.57%
18.24%
12.87%
20.90%
Other Income
4.50
2.59
73.75%
1.62
5.08
-68.11%
1.42
9.94
-85.71%
10.53
6.63
58.82%
Interest
22.53
22.32
0.94%
17.57
23.26
-24.46%
23.65
17.76
33.16%
24.64
19.52
26.23%
Depreciation
45.84
38.19
20.03%
43.47
34.61
25.60%
42.71
30.98
37.86%
39.82
30.08
32.38%
PBT
19.39
22.62
-14.28%
52.57
64.09
-17.97%
22.77
48.55
-53.10%
21.79
69.60
-68.69%
Tax
4.29
6.07
-29.32%
9.39
19.01
-50.60%
4.95
13.68
-63.82%
5.58
20.84
-73.22%
PAT
15.09
16.56
-8.88%
43.18
45.08
-4.21%
17.82
34.87
-48.90%
16.21
48.76
-66.76%
PATM
2.74%
3.07%
6.80%
8.05%
3.37%
7.28%
2.76%
9.05%
EPS
1.42
1.56
-8.97%
4.06
4.25
-4.47%
1.67
3.28
-49.09%
1.52
4.60
-66.96%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
2,303.47
2,291.92
2,056.17
1,904.65
1,777.58
1,326.59
1,159.72
Net Sales Growth
8.82%
11.47%
7.96%
7.15%
34.00%
14.39%
 
Cost Of Goods Sold
1,215.06
1,224.80
1,056.02
989.29
1,000.15
821.27
720.43
Gross Profit
1,088.41
1,067.12
1,000.15
915.36
777.43
505.32
439.29
GP Margin
47.25%
46.56%
48.64%
48.06%
43.74%
38.09%
37.88%
Total Expenditure
1,944.78
1,935.93
1,642.85
1,497.01
1,415.38
1,131.46
956.09
Power & Fuel Cost
-
109.37
94.21
66.27
57.95
49.86
35.03
% Of Sales
-
4.77%
4.58%
3.48%
3.26%
3.76%
3.02%
Employee Cost
-
276.33
238.14
204.73
175.46
131.38
103.25
% Of Sales
-
12.06%
11.58%
10.75%
9.87%
9.90%
8.90%
Manufacturing Exp.
-
178.96
150.78
139.47
106.97
80.61
47.96
% Of Sales
-
7.81%
7.33%
7.32%
6.02%
6.08%
4.14%
General & Admin Exp.
-
97.48
73.17
65.42
49.09
28.39
27.30
% Of Sales
-
4.25%
3.56%
3.43%
2.76%
2.14%
2.35%
Selling & Distn. Exp.
-
31.96
24.09
22.65
16.49
12.46
12.54
% Of Sales
-
1.39%
1.17%
1.19%
0.93%
0.94%
1.08%
Miscellaneous Exp.
-
17.03
6.44
9.18
9.27
7.49
9.58
% Of Sales
-
0.74%
0.31%
0.48%
0.52%
0.56%
0.83%
EBITDA
358.69
355.99
413.32
407.64
362.20
195.13
203.63
EBITDA Margin
15.57%
15.53%
20.10%
21.40%
20.38%
14.71%
17.56%
Other Income
18.07
16.15
29.19
33.44
4.36
34.07
8.82
Interest
88.39
88.19
79.64
99.90
111.11
101.11
58.71
Depreciation
171.84
164.19
125.45
105.98
86.41
61.53
32.88
PBT
116.52
119.75
237.42
235.19
169.04
66.57
120.86
Tax
24.21
25.99
69.81
43.86
34.90
-1.55
23.64
Tax Rate
20.78%
21.70%
29.40%
18.65%
20.65%
-2.33%
19.56%
PAT
92.30
93.76
167.61
191.33
134.14
68.12
97.22
PAT before Minority Interest
92.30
93.76
167.61
191.33
134.14
68.12
97.22
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
4.01%
4.09%
8.15%
10.05%
7.55%
5.13%
8.38%
PAT Growth
-36.46%
-44.06%
-12.40%
42.63%
96.92%
-29.93%
 
Unadjusted EPS
8.67
8.83
15.83
20.78
21.37
44.27
63.56

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
1,558.41
1,482.64
1,330.45
856.80
722.10
358.42
Share Capital
106.44
106.03
105.76
82.38
82.13
77.84
Total Reserves
1,446.60
1,370.75
1,218.84
771.47
637.03
277.22
Non-Current Liabilities
295.49
174.30
132.34
428.11
363.73
203.92
Secured Loans
258.71
141.66
124.56
353.61
303.68
188.17
Unsecured Loans
0.00
0.00
0.00
106.13
0.00
0.00
Long Term Provisions
30.05
20.84
14.59
6.77
5.13
3.93
Current Liabilities
1,423.90
1,306.89
1,120.75
883.75
802.49
710.87
Trade Payables
488.31
312.33
263.10
247.61
230.81
227.47
Other Current Liabilities
244.50
231.26
199.11
141.05
133.34
164.25
Short Term Borrowings
684.21
758.52
644.17
481.42
431.63
312.18
Short Term Provisions
6.89
4.78
14.37
13.66
6.70
6.97
Total Liabilities
3,277.80
2,963.83
2,583.54
2,168.66
1,888.32
1,273.21
Net Block
1,629.07
1,480.80
1,229.93
1,021.03
801.01
499.27
Gross Block
2,105.42
1,793.75
1,418.58
1,106.33
986.17
623.32
Accumulated Depreciation
476.35
312.95
188.65
85.30
185.16
124.04
Non Current Assets
1,814.84
1,716.23
1,443.71
1,165.92
1,024.41
696.70
Capital Work in Progress
109.63
163.18
143.26
69.60
109.67
116.10
Non Current Investment
3.40
3.40
3.40
7.04
7.45
0.00
Long Term Loans & Adv.
25.58
29.36
25.95
29.22
93.94
68.50
Other Non Current Assets
47.16
39.50
41.17
39.03
12.34
12.82
Current Assets
1,462.96
1,247.59
1,139.82
1,002.73
862.27
574.81
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
681.94
584.78
509.05
487.09
475.50
328.10
Sundry Debtors
709.94
570.59
567.61
444.86
285.07
194.88
Cash & Bank
3.02
3.06
4.09
28.77
58.88
23.20
Other Current Assets
68.06
30.53
34.07
18.14
42.82
28.64
Short Term Loans & Adv.
35.22
58.63
25.01
23.86
22.75
19.80
Net Current Assets
39.05
-59.30
19.07
118.98
59.78
-136.06
Total Assets
3,277.80
2,963.82
2,583.53
2,168.65
1,888.32
1,273.21

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
297.66
342.49
331.99
181.97
-64.71
121.23
PBT
119.75
237.42
235.19
169.04
66.57
120.86
Adjustment
255.27
216.47
199.38
200.57
136.26
83.06
Changes in Working Capital
-52.04
-49.48
-52.45
-154.37
-250.72
-59.27
Cash after chg. in Working capital
322.99
404.41
382.12
215.23
-47.89
144.65
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-25.32
-61.91
-50.13
-33.26
-16.82
-23.42
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-252.88
-384.15
-288.67
-312.20
-396.95
-311.82
Net Fixed Assets
-254.84
-394.43
-354.15
-76.75
-353.86
Net Investments
-6.57
-1.22
-24.40
-7.01
-18.65
Others
8.53
11.50
89.88
-228.44
-24.44
Cash from Financing Activity
-44.77
42.24
-53.61
103.32
486.08
203.03
Net Cash Inflow / Outflow
0.02
0.59
-10.30
-26.91
24.42
12.44
Opening Cash & Equivalents
3.00
2.42
12.81
39.53
15.11
2.67
Closing Cash & Equivalent
2.97
3.00
2.42
12.81
39.53
15.11

Financial Ratios

Standalone /

Consolidated
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
145.91
139.28
125.25
499.30
419.61
189.14
ROA
3.00%
6.04%
8.05%
6.61%
4.31%
7.64%
ROE
6.19%
11.97%
18.12%
18.65%
14.47%
33.42%
ROCE
8.22%
13.68%
16.52%
16.35%
13.74%
19.96%
Fixed Asset Turnover
1.18
1.29
1.53
1.73
1.66
1.87
Receivable days
101.97
100.40
95.66
73.56
65.47
61.02
Inventory Days
100.87
96.48
94.12
97.00
109.61
102.73
Payable days
72.80
61.13
59.14
58.52
69.29
86.77
Cash Conversion Cycle
130.03
135.75
130.64
112.05
105.79
76.98
Total Debt/Equity
0.67
0.66
0.64
1.20
1.14
1.54
Interest Cover
2.36
3.98
3.35
2.52
1.66
3.06

News Update:


  • Laurus Labs agrees to acquire stake in Phekolong Pharmaceuticals
    19th Sep 2019, 09:52 AM

    This transaction will provide the company access to the South African public antiretroviral sector

    Read More
  • Laurus Labs gets EIR from USFDA for API Units 1& 3 at Visakhapatnam
    5th Sep 2019, 11:02 AM

    In FDF segment, the company also received GF ERP approval for FDC TLE 400 for supply in GF funded projects

    Read More
  • Laurus Labs - Quarterly Results
    2nd Aug 2019, 17:25 PM

    Read More
  • Laurus Labs, Rising Pharmaceuticals launch Pregabalin Capsules in US market
    22nd Jul 2019, 12:18 PM

    Pregabalin Capsules had U.S. sales of approximately $5,497 million for the 12 months ending March 2019

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.